Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)
Frequently Asked Questions About Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)
How can investors track Day One Biopharmaceuticals' performance?
Investors can track Day One Biopharmaceuticals' performance by monitoring its stock price on NASDAQ under the ticker 'DAWN.' Additionally, the company regularly releases financial reports, press releases, and updates on clinical trials through its investor relations website, which provides further insights into its business operations and growth potential.
How does Day One Biopharmaceuticals engage with the patient community?
Day One Biopharmaceuticals actively engages with the patient community through outreach programs, collaborations with pediatric oncology advocates, and participation in cancer awareness initiatives. By fostering open communication and feedback from patients and families, the company aims to align its research priorities with real-world needs.
How does Day One Biopharmaceuticals ensure safety in its drug development?
Day One Biopharmaceuticals prioritizes safety in its drug development process by adhering to rigorous regulatory standards and conducting comprehensive preclinical and clinical trials. The company employs a robust framework for evaluating the efficacy and safety of its candidates, ensuring that the treatments are not only effective but also safe for pediatric patients.
Is Day One Biopharmaceuticals publicly traded?
Yes, Day One Biopharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol 'DAWN.' The company went public in 2021 to raise capital for further development of its drug candidates and to advance its mission of addressing pediatric cancer.
What are the stages of clinical development in Day One Biopharmaceuticals?
The stages of clinical development at Day One Biopharmaceuticals typically include preclinical research, followed by phase 1, phase 2, and phase 3 clinical trials. Each phase is crucial for assessing the safety, efficacy, and dosing of drug candidates, ultimately leading to regulatory approval if successful.
What challenges does Day One Biopharmaceuticals face?
Day One Biopharmaceuticals faces challenges typical of the biopharmaceutical industry, including lengthy regulatory processes, high research and development costs, and the complexities associated with clinical trial recruitment, especially in the pediatric population. Additionally, the company must navigate the competitive landscape of oncology therapeutics.
What does Day One Biopharmaceuticals, Inc. do?
Day One Biopharmaceuticals, Inc. is a biopharmaceutical company focused on delivering innovative, targeted therapies for patients with cancer. The company is particularly dedicated to developing treatments for pediatric populations, addressing significant unmet medical needs within this demographic through advanced drug development and clinical research.
What is Day One Biopharmaceuticals' approach to clinical trials?
Day One Biopharmaceuticals adopts a strategic and patient-centric approach to clinical trials, focusing on innovative designs that maximize the potential for successful outcomes. The company works closely with regulatory bodies and clinical experts to ensure trials are well-structured and address the specific needs of pediatric patients.
What is the lead product candidate of Day One Biopharmaceuticals?
Day One Biopharmaceuticals' lead product candidate is a drug known as DB-1303, which is targeted at treating pediatric patients with specific types of cancer. This candidate is designed to address the underlying genetic drivers of the disease, focusing on providing precise and effective treatment tailored for young patients.
What is the mission of Day One Biopharmaceuticals, Inc.?
The mission of Day One Biopharmaceuticals, Inc. is to develop and deliver breakthrough therapies for children with cancer. The company seeks to transform the treatment landscape by prioritizing the unique needs of pediatric patients and ensuring that they have access to effective and safe treatment options.
What is the significance of pediatric cancer research?
Pediatric cancer research is significant because it addresses a unique group of patients who often respond differently to treatments compared to adults. Advancements in this field aim to develop targeted therapies that consider the biological differences in children, ultimately seeking to improve survival rates and reduce long-term side effects of treatments.
What partnerships does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals collaborates with various academic institutions, research organizations, and healthcare providers to accelerate the development of its therapies. These partnerships are vital for enhancing research capabilities, sharing expertise, and conducting clinical trials effectively.
What role does the management team play in Day One Biopharmaceuticals?
The management team at Day One Biopharmaceuticals plays a critical role in guiding the company’s strategic direction, overseeing clinical development, and ensuring financial health. Comprised of seasoned professionals from the biotechnology sector, the team is responsible for fostering innovation, building partnerships, and steering the company's mission towards impactful patient outcomes.
What sets Day One Biopharmaceuticals apart from other companies?
What sets Day One Biopharmaceuticals apart is its exclusive focus on pediatric oncology, combined with its commitment to developing innovative, targeted therapies that address the specific needs of children with cancer. The company’s dedication to this underserved population results in a tailored approach to drug development that prioritizes efficacy and safety.
What types of cancer does Day One Biopharmaceuticals focus on?
Day One Biopharmaceuticals focuses primarily on pediatric cancers, including but not limited to neuroblastoma, leukemia, and glioma. By concentrating on these challenging areas, the company aims to create targeted therapies that can significantly improve treatment outcomes for children suffering from these diseases.
When was Day One Biopharmaceuticals, Inc. founded?
Day One Biopharmaceuticals, Inc. was founded in 2018. The company was established to leverage scientific expertise and innovative approaches to develop new therapies specifically designed for children with cancer, aiming to improve outcomes and quality of life for young patients.
Who are the founders of Day One Biopharmaceuticals?
Day One Biopharmaceuticals was founded by a team of experienced professionals from the biopharmaceutical industry, including scientists, clinicians, and entrepreneurs. Their collective expertise in drug development, oncology, and pediatric healthcare has been instrumental in driving the company's vision and strategic goals.
What is the current price of Day One Biopharmaceuticals, Inc. - Common Stock?
The current price of Day One Biopharmaceuticals, Inc. - Common Stock is 7.970
When was Day One Biopharmaceuticals, Inc. - Common Stock last traded?
The last trade of Day One Biopharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025